Abstract: Subarachnoid haemorrhage (SAH) has a high mortality and morbidity rate. Early SAH diagnosis allows the early treatment of a ruptured cerebral aneurysm, which improves the prognosis. Diagnostic cerebrospinal fluid (CSF) analyses may be performed after a negative computed tomography scan, but the precise analytical methods to be used have been debated. Here, we summarize the scientific evidence for different CSF methods for SAH diagnosis and describe their implementation in different countries. The principle literature search was conducted using PubMed and Scopus with the search items "cerebrospinal fluid", "subarachnoid haemorrhage", and "diagnosis". CSF analyses for SAH include visual examination, red blood cell counts, spectrophotometry for oxyhaemoglobin or bilirubin determination, CSF cytology, and ferritin measurement. The methods vary in availability and performance. There is a consensus that spectrophotometry has the highest diagnostic performance, but both oxyhaemoglobin and bilirubin determinations are susceptible to important confounding factors. Visual inspection of CSF for xanthochromia is still frequently used for diagnosis of SAH, but it is advised against because spectrophotometry has a superior diagnostic accuracy. A positive finding of CSF bilirubin is a strong indicator of an intracranial bleeding, whereas a positive finding of CSF oxyhaemoglobin may indicate an intracranial bleeding or a traumatic tap. Where spectrophotometry is not available, the combination of CSF cytology for erythrophages or siderophages and ferritin is a promising alternative.
Introduction
Subarachnoid haemorrhage (SAH) accounts for approximately 5% of all strokes and has a yearly incidence of approximately 1 in 10,000 persons [1] . Importantly, SAH both has a high fatality (30%-70%) [2] and may occur at an early age compared with other causes of stroke [3] . In the majority of cases, SAH is caused by a spontaneous rupture of an aneurysm in the arterial circulation of the brain. Typical initial symptoms are severe headache with a sudden onset ("thunderclap headache"), neck stiffness, vomiting, confusion, or loss of consciousness. Tools for SAH diagnosis include imaging and cerebrospinal fluid (CSF) analyses. There is no definite international consensus on a preferred diagnostic algorithm, and procedures differ between countries and regions, which may have an impact on patients in terms of diagnosis, treatment, and prognosis. In this review, we aim to discuss available CSF methods for SAH diagnosis, clarify their strengths and weaknesses, and outline their use on a global scale, focusing on recent guidelines and experiences from laboratory medicine in the UK, Germany, Sweden, the Netherlands, Austria, and the USA.
Methods
The literature search for this review was based on the intention to include all up-to-date studies to accurately describe the current scientific basis for CSF-based diagnostics of SAH and to illustrate the variability in methods between countries. We performed searches on PubMed with the principal search items "cerebrospinal fluid", "subarachnoid haemorrhage", and "diagnosis". We did additional searches with the added keywords "spectrophotometry", "oxyhaemoglobin", "methaemoglobin", "bilirubin", "ferritin", and "siderophages". The database Scopus was used to identify more recent publications citing selected references. From identified references, we included relevant clinical studies, review articles, editorials, and comments. Selection criteria included a judgment on the importance of the studies, where prospective studies, large case series, guidelines, and consensus documents were prioritized. The general search was restricted to articles in English published after 1990, but since we aimed to review methods across different countries, we also included specifically selected articles written in other languages. We also examined older important publications that we were previously aware of. Finally, we also here present novel data from a Swedish control survey of SAH diagnostics.
The importance of early diagnosis
An incorrect initial diagnosis of SAH patients is common and is associated with worse prognosis [4] . SAH patients may initially present with less serious clinical symptoms (called sentinel headache) caused by a small bleeding (warning leak), followed by a manifest SAH, often within 2 weeks [5] . Sentinel headache has been reported in up to 40% of SAH patients [6] . It is of uttermost importance to identify these patients because interventional therapy at this stage may hinder a life-threatening bleeding and significantly improve prognosis [7] [8] [9] .
Diagnostic methods
Clinical examination is insufficient for SAH diagnosis. The most commonly used first line of investigation is noncontrast computed tomography (CT) of the brain. CT has an excellent sensitivity for SAH in the acute stage, especially using modern scanners, with sensitivities up to 98%-100% within the first hours from symptom onset [10, 11] . However, subtle abnormalities may not be detected by inexperienced or nonspecialized physicians, and expert neuroradiologists are not available at all hospitals [4] . However, because subarachnoid blood is rapidly cleared from the brain, the sensitivity drops quickly. Six hours after onset, the sensitivity of a CT scan for finding an SAH is approximately 86%-93% [11, 12] , and it decreases to approximately 50% after 1 week (Table 1) [13] . Importantly, these figures are likely to be even lower when scans are evaluated by nonspecialized radiologists, as is often the case in smaller hospitals or outside business hours. A conventional cerebral angiography is usually performed on patients with a positive CT scan to locate a possible aneurysm for interventional therapy. For patients with a negative CT scan where the clinical suspicion remains strong, more investigations are needed [20] . Fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) may have higher sensitivity than CT [21] , but in clinical practice, the choice after a negative CT scan most often stands between a conventional cerebral angiography and a lumbar puncture (LP) for CSF analyses. A cerebral angio graphy is resource demanding, carries a slight risk for stroke as a complication, and may result in false-positive results and unwarranted interventions because incidental aneurysms are found in approximately 5% of the population [22] . These factors usually make CSF analyses preferred as a second-line of investigation after a negative CT scan.
CSF analyses
There are several widely used CSF analyses for SAH, with different diagnostic performance, availability, and High, but accurate numbers are missing [19] technical requirements. A consequence in clinical practice of differences between methods and how they are implemented is that patients may receive different diagnoses and treatments at different hospitals.
Visual inspection
The most basic CSF method for SAH is the visual evaluation of discoloration. For this, the sample is usually centrifuged and the supernatant compared with a tube of water, held against a well-illuminated white background. Normal CSF is uncolored, and transparent. After an SAH, a yellowish or reddish tint is seen due to bilirubin (called xanthochromia) or oxyhaemoglobin. According to a survey from 2002, most US laboratories use visual assessment of xanthochromia as their main CSF analysis of SAH [23] . However, the sensitivity of the human color vision is not sufficient to detect a very small amount of bilirubin, which may appear as transparent as water [14, 24] . The human eye also has difficulty in assessing xanthochromia of a predominantly red fluid, which makes it problematic to visually distinguish a red sample after a traumatic tap from a bilirubin-rich sample after an SAH. A traumatic tap may occur when the LP needle punctuates a blood vessel. This has been estimated to happen in 10%-20% of LPs but may be even more frequent depending on the definitions of the cutoff towards a normal CSF erythrocyte count [25] [26] [27] [28] [29] . A traumatic tap introduces erythrocytes in the CSF, which may undergo in vitro lysis and release their oxyhaemoglobin content. On visual inspection, approximately 80% of CSF samples with significant bilirubin levels seem red rather than yellow due to the presence of oxyhaemoglobin [30] . In sum, visual inspection has poor diagnostic sensitivity for SAH (Table 1 ) [14, 15] and a higher proportion of laboratory technicians identify bilirubin when using a spectrophotometer compared with visual inspection [24, 31] . The subjectivity of visual evaluation also makes it difficult to perform comparisons over time. There are also other possible causes of CSF discoloration, as explained in the Confounding Factors section.
Red blood cell count
In principle, normal CSF should not contain erythrocytes, but the red blood cell count expected in CSF after an SAH, differentiating it from a traumatic tap, is not well defined. Cell counts are sometimes performed on serial tubes, to detect declining red blood cell counts, indicating a traumatic tap (the so-called three-tube method). However, because a traumatic tap may result in discontinuing and resuming bleedings and may occur also in the presence of an SAH, the serial tube method is unreliable [32, 33] .
Spectrophotometry
Spectrophotometry is used to detect the absorption spectrum of CSF pigments, and the presence of different biomarkers may be estimated from the absorption curve. It is a rapid ( < 1 min) technique that requires a small sample amount (50-500 µL) [28] . Because sensitivity and specificity vary for different markers that may be elevated depending on the duration since symptom onset, the laboratory technician must know the time point of symptom debut, sampling, and centrifugation to perform a sound interpretation (Table 1) .
Oxyhaemoglobin
After an SAH, the erythrocytes in the CSF will gradually lyse and release their intracellular haemoglobin. This process starts shortly (2-4 h) after the bleeding, and oxyhaemoglobin can be detected in CSF from approximately 2-12 h after ictus [34] . Oxyhaemoglobin, the oxygenated form of haemoglobin, has an absorbance maximum around 415 nm, in the violet region of the optical spectrum ( Figure 1A ) [28] . Minor secondary absorbance peaks, sometimes referred to as Soret bands, may be detected at 540 and 580 nm, in the green region of the optical spectrum.
Bilirubin
Oxyhaemoglobin is metabolized to bilirubin through enzymatic reactions by macrophages in vivo. This does not occur in vitro in tapped CSF (except in samples with very high white blood cell count), which strongly reduces the risk for false-positive results caused by a traumatic tapping. Bilirubin has a broad maximum absorption peak in the blue region of the optical spectrum at 450-460 nm [28] . On spectrophotometry of an acute bleeding, where oxyhaemoglobin is still present in high concentrations, bilirubin may be visible as a gentle slope to the right of the sharp oxyhaemoglobin peak ( Figure 1B ). As an alternative to using a spectrophotometer, CSF bilirubin may also be measured by the modification of the direct diazo methods used for bilirubin measurements in serum or plasma. This has been suggested as a screening instrument to identify samples that need to be further analyzed by spectrophotometry [35, 36] , but difficulties regarding technical analyses and method standardization may hinder a broad implementation of this tentative approach [37] .
Methaemoglobin
Methaemoglobin is haemoglobin with ferric (Fe
3+
) instead of ferrous iron (Fe 2+ ) in the haem group, with a broad absorbance maximum peak at 403-410 nm. Normally, methaemoglobin is present in very small amounts, but it has been reported in CSF of patients with subdural haematoma or an enclosed bleeding, giving the CSF a brownish color [38] . A spontaneous oxidation of the haem group occurs around 10 days after a bleed, irrespective of cause [39] , which may be useful to distinguish between a traumatic tap and a cerebral haemorrhage [40] .
Ferritin
Ferritin is an iron-storage protein complex that removes toxic iron released from the metabolized haemoglobin. The production of this large protein takes some time, and therefore, CSF ferritin has a lower sensitivity in the first hours after SAH and is not advocated for diagnostic use at an early stage [41, 42] . A first increase is possibly due to the activation of macrophages. It takes approximately 3 days for the CSF ferritin levels to consistently increase and 7-10 days to reach over 1000 ng/mL [43] . For comparison, control CSF has been reported to have an average ferritin level of approximately 4 ng/mL, whereas CSF contaminated by a traumatic LP has been reported to have an average ferritin level of approximately 9 ng/mL [43] .
One conservative reference limit that has been proposed is 12 ng/mL [44] , and in a prospective study, a cutoff of 15 ng/mL achieved 95% sensitivity and specificity for SAH (Table 1) [18] . Importantly, CSF ferritin levels remain high long after CSF bilirubin decrease or become undetectable [42, 43] .
Siderophages
SAH induces an inflammatory response that includes macrophage activation. Macrophages that have consumed erythrocytes develop haemosiderin storage and are called siderophages. Cytological finding of CSF siderophages have a low sensitivity within the first 3 days after an intracranial bleeding, making them unsuitable for early diagnosis, but later in the process, they have high sensitivity and specificity, and they may even be detected for several months after an insult (Table 1) [32, 19] . In combination with erythrophages (macrophages that do not have haemosiderin inside), they can give important clues about the age and dynamics of the bleeding [45] .
Other methods
Other CSF biomarkers tested for SAH diagnosis require further evaluation (for example, urine test stripes for rapid detection of red blood cells in CSF [46] ) or have shown inconclusive results (for example, CSF D-dimer [12, 47, 48] ).
Regional practices
The implementation of the methods used to diagnose SAH after a negative CT scan outlined above differs between countries and regions, even among specialized centers. Here, we experiences from different countries, focusing on official UK guidelines, a recently completed survey among Swedish laboratories, and the authors own experiences from practice in Germany, Austria, Switzerland, and USA.
United Kingdom
The UK National External Quality Assessment Service (NEQAS) guidelines stress the use of spectrophotometry and have reduced the use of visual assessment for SAH diagnosis in the UK [49, 50] . These guidelines emphasize the use of bilirubin because this is solely produced in vivo, as opposed to oxyhaemoglobin and methaemoglobin [50] , reducing the risks for false-positive results. Accordingly, the UK guidelines state that the sampling should be no < 12 h after the possible bleeding. The UK guidelines advocate scanning between 350 and 600 nm to allow interpretation of the curve for bilirubin, oxyhaemoglobin, and methaemoglobin (which is considered a probable artefact of oxyhaemoglobin conversion and given the same significance as oxyhaemoglobin). The net bilirubin absorbance (NBA) is calculated according to Chalmers' modified method [51] , but the laboratory technician should also measure the net oxyhaemoglobin absorbance (NOA) at the maximum oxyhaemoglobin absorbance. The absence of bilirubin and oxyhaemoglobin (NBA ≤ 0.007 AU and NOA ≤ 0.02 AU) is reported as "no evidence to support SAH". Small amounts of oxyhaemoglobin (NBA ≤ 0.007 AU and 0.1 AU > NOA > 0.002 AU) is also reported as "no evidence to support SAH", but an oxyhaemoglobin peak large enough to allow impairment of bilirubin detection (NBA ≤ 0.007 AU and NOA ≥ 0.1 AU) is reported as "SAH not excluded". If bilirubin is detected alone (NBA > 0.007 AU and NOA ≤ 0.02 AU or NOA > 0.02 but with no visible oxyhaemoglobin peak), the laboratory technician considers the serum bilirubin and CSF protein levels because these may give false-positive bilirubin results. If serum bilirubin is low ( ≤ 20 μmol/L), the result is reported as "consistent with SAH", and if serum bilirubin is high ( > 20 μmol/L), the NBA is adjusted accordingly and reported as "consistent with SAH" (if still increased) or "not supportive of SAH" (if the increase depended on serum bilirubin). Increased bilirubin (NBA > 0.007 AU) in the presence of elevated CSF protein levels ( > 1.0 g/L) is reported as a possible SAH, but other sources of increased CSF bilirubin must then also be considered. Finally, a concurrent finding of bilirubin and oxyhaemoglobin (NBA > 0.007 AU and NOA > 0.02 AU with visible oxyhaemoglobin peak) is reported as "consistent with SAH". This scheme has become influential, but its use is not trivial, and it requires trained staff and a substantial through-flow of samples to maintain observer skills.
Sweden
During 2010, a survey of CSF analyses in SAH investigations in Sweden was performed. A questionnaire was sent out to all Swedish laboratories participating in quality control programs organized by the External Quality Assurance in Laboratory Medicine in Sweden (EQUALIS) (n = 24). Twenty-two laboratories reported that they used spectrophotometry as their main method. Ten of these measured absorbance at 415 nm (with or without a full curve); five laboratories stated that they used spectrophotometry but did not further specify how; five laboratories followed the UK NEQAS guidelines; two laboratories measured absorbance at 415 nm plus direct measurement of CSF bilirubin; and two laboratories evaluated the samples visually and did cell counts. To investigate if these differences may result in different patient management, two survey samples were sent out (prepared at the Clinical Neurochemistry Laboratory in Mölndal by deidentified CSF samples from the routine workflow). Each sample had a (fictional) medical history. The first sample was presented as "male, 34 years old, acute headache, debuted 8 h before sampling. Bleeding?" Spectrophotometry at Mölndal showed a distinct oxyhaemoglobin peak (absorbance, 415 nm, 0.16 AU; Figure 2A ). Of 17 responding laboratories, 11 reported that SAH could not be excluded (9 specifically answered that the result also was consistent with a traumatic tap), three reported that the result indicated SAH, and two reported that SAH was unlikely. The second sample was presented as "woman, 66 years old, has been feeling uncomfortable since 2-3 days. In the beginning, she also had a headache. Bleeding?" Spectrophotometry at Mölndal showed a distinct bilirubin peak (absorbance, 451 nm, 0.043 AU; Figure 2B ). Of 15 responding laboratories, eight reported that the result indicated SAH if serum bilirubin < 20 μmol/L, five reported that the result indicated SAH, 1 reported that the result excluded SAH, and one responded that results without accompanying blood samples were not interpreted. In sum, for a sample with a significant spectrophotometric oxyhaemoglobin peak 8 h after headache onset, SAH was reported as the only interpretation by three laboratories and unlikely by three laboratories. A more careful interpretation, that SAH could not be excluded but that a traumatic tap must also be considered, was only reported by 11 of 17 laboratories. The reports were more consistent when the sample was dominated by a significant bilirubin peak, where only 1 of 15 laboratories answered that the results excluded SAH.
Germany, Austria, Switzerland, the Netherlands, and USA
In the German-speaking countries (Germany, Austria, and Switzerland), the use of absorbance spectrophotometry for SAH diagnostics is still uncommon. Instead, CSF ferritin measurement is the method of choice at most centers because it is easily available on the routine laboratory instruments that already measures CSF total protein, glucose, and lactate. Current guidelines by the German Society of CSF Diagnostics and Clinical Neurochemistry (DGLN) suggest visual inspection including the "threetube method", cell differentiation, and measurement of ferritin when looking for an SAH [52] , but measuring the absorbance with a spectrophotometer was recently named as alternative method [45] .
In the Netherlands, national guidelines for CSF analyses following SAH are still awaited at time of writing. The Erasmus Medical Center has adopted the UK NEQAS guidelines using Chalmers calculation. A computer-based iterative method to interpret spectrophotometric results (described below) have been developed by Dutch researchers [16] . A recent review from a leading national center on SAH recommended visual analysis [53] , which resulted in an educative scientific exchange [54] [55] [56] [57] .
In the USA, LP is acknowledged for SAH examination (visual inspection and cell counts) after a negative CT scan, but spectrophotometry is still uncommon [58] . There is not a formal quality control program in use for CSF bilirubin testing because it is not a procedure practiced widely in the country. 
Confounding factors
All CSF analyses described above are subject to confounding factors related to the LP, sample handling, or interpretation.
Timing of the LP
The timing of the LP in relation to symptom onset has a pivotal impact on all results (Figure 3 ). CSF production and turnover replaces the entire CSF volume four times each day [59] , making it a dynamic compartment. Erythrocytes may be found in the lumbar region approximately 2 h after an intracranial bleeding [38] . Oxyhaemoglobin also starts to appear around this time point, whereas bilirubin first shows 12 h after the bleeding [50, 60] . For the detection of oxyhaemoglobin, it is recommended that sampling is done no sooner than 6 h after symptom onset, when a large enough CSF volume has passed from intracranial areas to the lumbar sack, making the lumbar sample representative. Because the oxyhaemoglobin peak diminishes over time, an isolated oxyhaemoglobin peak without any signs of bilirubin in a sample taken more than 12 h after symptom onset suggests contamination by a traumatic tap.
Sample transport and storage
The transport of the sample to the laboratory should be done swiftly, and not in a pneumatic tube, to avoid in vitro haemolysis [61] because this may lead to false-positive results for oxyhaemoglobin and impair the ability to detect bilirubin. At the laboratory, the sample must be centrifuged as soon as possible if a spectrophotometry analysis should be done. If the red cell count is the method in use, centrifugation should not be done. UK guidelines [50] and others [62] sampling, whereas Swedish laboratories are generally recommended to centrifuge within 30 min. These cutoffs are arbitrary, and in our clinical experience, haemolysis may start even within 30 min in some samples, whereas it may take several hours in other samples. The supernatant should be stored at 4°C in the dark until analysis to avoid ultraviolet light-dependent degradation of bilirubin, producing false-negative results [63] .
False-positive bilirubin
Bilirubin may be false positive due to hyperbilirubinemia (a serum sample should therefore be taken together with CSF to allow adjustment for this), significant bloodbrain barrier damage, malignancies, or treatment with rifampicin [28, 64] .
Use the least bloody sample
Although the "three-tube method" is susceptible to false results, serial tubes may be useful because an initial bloody sample portion may be discarded immediately and the least bloodstained sample used for analysis (at the laboratory, red blood cell counts may be done on partial samples from all available tubes, and the sample with the lowest count used for spectrophotometry). A clearing between the first tube and the last tube cannot exclude SAH. In a study by Heasley et al. [65] , clearing, defined as a 25% reduction of RBC between the first tube and the fourth tube, was present even in cases with ruptured aneurysms.
Interpreting the spectrophotometry
Spectrophotometry is generally appreciated as the gold standard method for CSF analyses of SAH, but there is no definite consensus on curve interpretation, neither in terms of the roles of oxyhaemoglobin vs. bilirubin nor on definitions of pathological cutoffs. One study [17] found low specificity and positive predictive value of spectrophotometry, recommending CT angiography as an alternative. However, such studies have typically not carefully adjusted for the presence of a traumatic tap masking the presence of bilirubin [66] . Gunawardena et al. suggest that patients with oxyhaemoglobin alone and a high suspicion of SAH may benefit from angiography, although the risk for aneurysm is low [67] . A result positive for bilirubin, with or without oxyhaemoglobin, means a high risk for a bleeding aneurysm and should lead to angiography if the CSF bilirubin cannot be explained otherwise. According to the UK guidelines, elevated oxyhaemoglobin and bilirubin is reported as consistent with SAH [50] , irrespective of CSF protein levels [68] . A problem is that a traumatic tap may lead to increased oxyhaemoglobin and together with either elevated CSF proteins or hyperbilirubinemia may lead to a spectroscopy result that is reported as "consistent with SAH" [69, 70] . If bilirubin is elevated without a visible oxyhaemoglobin peak and CSF protein levels are raised, meningitis or other diagnoses are more likely [68] . It is therefore important that the clinicians carefully consider the clinical history, serum bilirubin concentrations, CSF protein levels as well as the number of LP attempts. Visual interpretation of the curve is prone to interobserver variability. Chalmers and Kiley [71] have described a standardized method to calculate NBA using a baseline drawn as tangent to the curve between 360 and 530 nm and measuring the distances from the baseline to the curve at 415 and 440 nm to compensate for the oxyhaemoglobin load. The method was later modified by Chalmers [51] , using a measurement at 476 nm only, where the influence from oxyhaemoglobin is so small that the bilirubin measurement does not need compensation. Viljoen et al. [72] have investigated the imprecision when calculating the NBA according to Chalmers' modification. When measuring the within-operator variability, they found a variation of 17% at the medical decision level suggested by the UK guidelines. To minimize the imprecision, they suggested the use of a software-assisted measurement. Recently, Collet et al. [73] proposed such a method, a webbased software to interpret CSF pigments, that is based on the NEQAS guidelines [73] . For clinicians and laboratory personnel, it is important that they are aware of the variability in the NBA calculation, especially when calculated on a single NBA cutpoint, as recommended in the UK guidelines [72, 74] . An iterative (step-by-step) method, where a computer program calculates the contributions from methaemoglobin, oxyhaemoglobin, and bilirubin from absorbance at 405, 414, and 455 nm, respectively, may be used [16] , but it has lower diagnostic accuracy than a derivative method, using a standard of serial dilutions of CSF with known bilirubin concentrations [75] , compared with angiography as gold standard.
Towards an optimal CSF biomarker for SAH?
There is a consensus that spectrophotometry has the highest diagnostic performance of CSF methods for SAH analyses, but visual evaluation of CSF samples is still widely in clinical use in some countries. The major disadvantages of spectrophotometry are equipment cost, the need for trained staff to interpret results, and the lack of a global consensus on the optimal usage of the method. In the absence of compelling study data defining its cost-benefit, the costs involved in purchase of the spectrophotometer system, in the maintenance of the equipment, and the skill level of the individuals who would perform the testing are hard to justify in some countries, including the USA. Bilirubin has a strong positive predictive value for SAH, but relying solely on bilirubin, ignoring oxyhaemoglobin as an indicator of bleeding, requires an approximately 12-h wait between symptom debut and CSF tapping, which may be a logistic problem with prolonged stay for the patient at the emergency ward, and in some cases, a medical risk because a delayed investigation increases the risk for an early rebleeding [76, 77] . CSF ferritin is a promising method but carries a risk for false-negative results early after a bleeding. Finally, in rare cases with negative CT scans and CSF examinations, transcranial Doppler sonography and CT/MRI angiography have been reported to be useful [78] .
Conclusions
Visual inspection of CSF for xanthochromia is still frequently used for CSF-based diagnosis of SAH, but it is advised against because spectrophotometric methods have superior diagnostic accuracy. Positive findings of CSF bilirubin in the early stages or of CSF ferritin in the later stages are strong indicators of an intracranial bleeding. A positive finding of CSF oxyhaemoglobin may indicate an intracranial bleeding or a traumatic tap. Rigorous control of confounding factors may reduce the risk for false results.
Studies that compare different methods have not been done, and therefore, it is hard to evaluate what method is preferable. Many factors (confounding factors as well as costs, knowledge of the staff, etc.) have to be accounted for in such a comparison. Today, deciding what method to use in a certain laboratory seems to be dependent on local knowledge, opinions, and thinking. In sum, more of a proven experience rather than evidence decides how the CSF sample will be handled, but guidelines built on research are being used more and more. However, the overall variability described in this review calls for the establishment of a global proficiency testing program for CSF-based SAH diagnostics.
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